A Study of Deucravacitinib to Treat LPP and FFA

NCT06091956 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-06-08

Study results available
· View outcomes & findings →

Summary

The purpose of this clinical research study is to learn more about the use of Deucravacitinib in the treatment of Lichen Planopilaris.

Conditions

  • Lichen Planopilaris

Interventions

DRUG

Deucravacitinib

6 milligram (mg) orally administrated, twice daily

Sponsors & Collaborators

Principal Investigators

  • Aaron Mangold, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2024-05-21
Completion
2024-12-24
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06091956 on ClinicalTrials.gov